Decreased soluble guanylate cyclase contributes to cardiac dysfunction induced by chronic doxorubicin treatment in mice [PDF]
, 2017 Aims: The use of doxorubicin, a potent chemotherapeutic agent, is limited by cardiotoxicity. We tested the hypothesis that decreased soluble guanylate cyclase (sGC) enzyme activity contributes to the development of doxorubicin-induced cardiotoxicity ...
Allen, Kaitlin +15 more
core +1 more source
Annals of Oncology, 2010 Cancer treatment has improved extraordinarily in recent years. The development of targeted therapies has widened the cardiotoxic spectrum of antineoplastic drugs. Optimum management of cardiovascular disease before and during antineoplastic treatment is essential to reduce morbidity and mortality in cancer patients.
I, Brana, J, Tabernero
openaire +2 more sources
Effects of Polyphenols on Oxidative Stress-Mediated Injury in Cardiomyocytes [PDF]
, 2017 Cardiovascular diseases are the main cause of mortality and morbidity in the world. Hypertension, ischemia/reperfusion, diabetes and anti-cancer drugs contribute to heart failure through oxidative and nitrosative stresses which cause cardiomyocytes ...
Bei, Roberto +10 more
core +2 more sources
Ranolazine Attenuates Trastuzumab-Induced Heart Dysfunction by Modulating ROS Production [PDF]
, 2018 The ErbB2 blocker trastuzumab improves survival in oncologic patients, but can cause cardiotoxicity. The late Na+ current inhibitor ranolazine has been shown to counter experimental HF, including doxorubicin cardiotoxicity (a condition characterized by ...
Carlo G. Tocchetti +16 more
core +3 more sources
Frontiers in Pharmacology, 2021 Anticancer chemotherapies have been shown to produce severe side effects, with cardiotoxicity from anthracycline being the most notable. Identifying risk factors for anticancer therapy-induced cardiotoxicity in cancer patients as well as understanding ...
Wendy Keung +2 more
doaj +1 more source
Characteristics of patients with haematological and breast cancer (1996–2009) who died of heart failure-related causes after cancer therapy [PDF]
, 2016 Aims: To describe the characteristics and time to death of patients with breast or haematological cancer who died of heart failure (HF) after cancer therapy.
Atherton, John +8 more
core +2 more sources
Bibliometric and visual analysis of doxorubicin-induced cardiotoxicity
Frontiers in Pharmacology, 2023 Background: Doxorubicin-induced cardiotoxicity represents a prevalent adverse effect encountered in patients undergoing treatment with doxorubicin. To date, there has been no bibliometric study to summarize the field of doxorubicin-induced cardiotoxicity.
Xiaoxiao Lin +3 more
doaj +1 more source
High incidence of Angina pectoris in patients treated with 5-fluorouracil - A planned surveillance study with 102 patients [PDF]
, 2003 Objective: Angina pectoris, arrhythmic sudden death and myocardial infarction, all these cardiac events have occasionally been reported during 5-fluorouracil (5-FU) chemotherapy.
Lersch, C. +4 more
core +1 more source
Prophylactic use of carvedilol to prevent ventricular dysfunction in patients with cancer treated with doxorubicin [PDF]
, 2018 Objective: Deterioration in ventricular function is often observed in patients treated with anthracyclines for cancer. There is a paucity of evidence on interventions that might provide cardio-protection.
Abrar, Mohammed Burhan +8 more
core +1 more source
Ageing alters the severity of Sunitinib-induced cardiotoxicity: Investigating the mitogen activated kinase kinase 7 pathway association [PDF]
, 2019 Anti-cancer drug Sunitinib is linked to adverse cardiovascular events, which have shown to involve mitogen activated kinase kinase 7 (MKK7) pathway. Sunitinib-induced cardiotoxicity in 3, 12 and 24 months old male Sprague-Dawley rats and MKK7 expression ...
Cooper, Samantha +4 more
core +1 more source